Ultragenyx Pharmaceutical (MEX:RARE) Inventories, Finished Goods : MXN217 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Ultragenyx Pharmaceutical Inventories, Finished Goods?

Ultragenyx Pharmaceutical's quarterly finished goods increased from Sep. 2023 (MXN220 Mil) to Dec. 2023 (MXN256 Mil) but then declined from Dec. 2023 (MXN256 Mil) to Mar. 2024 (MXN217 Mil).

Ultragenyx Pharmaceutical's annual finished goods increased from Dec. 2021 (MXN117 Mil) to Dec. 2022 (MXN181 Mil) and increased from Dec. 2022 (MXN181 Mil) to Dec. 2023 (MXN256 Mil).

Ultragenyx Pharmaceutical Inventories, Finished Goods Historical Data

The historical data trend for Ultragenyx Pharmaceutical's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultragenyx Pharmaceutical Inventories, Finished Goods Chart

Ultragenyx Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventories, Finished Goods

Get a 7-Day Free Trial

63.28

116.65

117.48

180.92

256.48

Ultragenyx Pharmaceutical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Inventories, Finished Goods	Get a 7-Day Free Trial															207.74	166.60	219.98	256.48	217.16

Ultragenyx Pharmaceutical Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

Ultragenyx Pharmaceutical (MEX:RARE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultragenyx Pharmaceutical Inc (MEX:RARE) » Definitions » Inventories, Finished Goods

Comparable Companies

Traded in Other Exchanges

RARE:USA 0LIF:UK UP0:Germany

Address

60 Leveroni Court, Novato, CA, USA, 94949

Website

https://www.ultragenyx.com

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.